@Article{Banach2023,
journal="Lekarz POZ",
issn="2450-3517",
volume="9",
number="6",
year="2023",
title="Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association",
abstract="Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular risk factor in Poland (3/4 of people). The LDL cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine cardiovascular risk and determines the aim and target of lipid-lowering treatment. Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalization of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterized by a lower risk of muscle complications and new cases of diabetes due to its different metabolism. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at the cardiovascular risk. This expert opinion presents information on the place and possibility of using pitavastatin in the treatment of lipid disorders.",
author="Banach, Maciej
and Surma, Stanisław
and Kapłon-Cieślicka, Agnieszka
and Mitkowski, Przemysław
and Dzida, Grzegorz
and Tomasik, Tomasz
and Mastalerz-Migas, Agnieszka",
pages="309--326",
url="https://www.termedia.pl/Position-paper-of-the-Polish-expert-group-on-the-use-of-pitavastatin-in-the-treatment-of-lipid-disorders-in-Poland-endorsed-by-the-Polish-Lipid-Association,98,52099,1,1.html"
}